Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. Read more about Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
What does a deep molecular response signify? Read more about What does a deep molecular response signify?
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. Read more about Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. Read more about Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. Read more about Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. Read more about David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma.
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. Read more about Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. Read more about How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox.
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Read more about Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
